Grant: Alliance Grants
University of Victoria
$49,892.00
Large scale expression of SARS-CoV-2 spike protein antigenic regions to aid development of kits to measure immunity to COVID-19 disease._x000d_
FY 2020-21
Summary
Testing for the presence of the SARS-CoV-2 virus (the causative agent of COVID-19 disease) and testing for immunity to the virus are critical tools needed to create informed public policy to combat the COVID-19 pandemic. The SARS-CoV-2 virus has a spike protein on its surface, and antibodies against certain regions of the spike protein are thought to block viral entry into cells, and thus, the presence of such antibodies in an individual indicate immunity to COVID-19 disease. The critical component of any assay to detect anti-SARS-CoV-2 antibody is recombinant spike protein or recombinant fragments of the spike protein. This proposal describes an approach to generate recombinant SARS-CoV-2 spike protein antibody binding regions at cost that are 100 to 1,000 times lower than the cost of producing spike protein using current methods. Our recombinant system uses the bacterium Bacillus subtilis to secrete recombinant spike protein into the growth medium, which allows a simple separation of the spike protein fragments from the bacterial cells. This recombinant bacterium can be cultivated in industrial size bioreactors using simple, inexpensive growth medium. The production of inexpensive spike protein regions will provide a competitive advantage for our industry partner and will be a useful tool in fighting the COVID-19 pandemic, especially in resource poor regions of the world.
Program
Alliance Grants
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
553524-2020
Name nom
Nano, Francis
Department département
Biochemistry and Microbiology
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
49892
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Large scale expression of SARS-CoV-2 spike protein antigenic regions to aid development of kits to measure immunity to COVID-19 disease._x000d_
Keyword
NSERC
Application summary
Testing for the presence of the SARS-CoV-2 virus (the causative agent of COVID-19 disease) and testing for immunity to the virus are critical tools needed to create informed public policy to combat the COVID-19 pandemic. The SARS-CoV-2 virus has a spike protein on its surface, and antibodies against certain regions of the spike protein are thought to block viral entry into cells, and thus, the presence of such antibodies in an individual indicate immunity to COVID-19 disease. The critical component of any assay to detect anti-SARS-CoV-2 antibody is recombinant spike protein or recombinant fragments of the spike protein. This proposal describes an approach to generate recombinant SARS-CoV-2 spike protein antibody binding regions at cost that are 100 to 1,000 times lower than the cost of producing spike protein using current methods. Our recombinant system uses the bacterium Bacillus subtilis to secrete recombinant spike protein into the growth medium, which allows a simple separation of the spike protein fragments from the bacterial cells. This recombinant bacterium can be cultivated in industrial size bioreactors using simple, inexpensive growth medium. The production of inexpensive spike protein regions will provide a competitive advantage for our industry partner and will be a useful tool in fighting the COVID-19 pandemic, especially in resource poor regions of the world.